-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Kyntra Bio, Lowers Price Target to $18

Benzinga·11/17/2026 12:27:57
Listen to the news
HC Wainwright & Co. analyst Matthew Keller maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $43 to $18.